Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeanne M Link

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Molecular Imaging|August 19, 2003
Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient resultsJoanne M Wells, David A Mankoff, Janet F Eary, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 22, 2008
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiolLanell M Peterson, David A Mankoff, Thomas Lawton, et al.
Clinical Nuclear Medicine|February 3, 2011
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapyEvan Y Yu, Mark Muzi, Joy A Hackenbracht, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2011
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PETBrenda F Kurland, Lanell M Peterson, Jean H Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2016
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast CancerBrenda F Kurland, Lanell M Peterson, Jean H Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 11, 2015
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging StudyLi Liu, Ann C Collier, Jeanne M Link, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matterAlexander M Spence, Mark Muzi, David A Mankoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcomeAlexander M Spence, Mark Muzi, Michael M Graham, et al.
Nuclear Medicine and Biology|October 9, 2007
Challenges in clinical studies with multiple imaging probesKenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Molecular Imaging and Biology|October 17, 2018
Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Molecular Imaging|August 19, 2003
Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient resultsJoanne M Wells, David A Mankoff, Janet F Eary, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 22, 2008
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiolLanell M Peterson, David A Mankoff, Thomas Lawton, et al.
Clinical Nuclear Medicine|February 3, 2011
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapyEvan Y Yu, Mark Muzi, Joy A Hackenbracht, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 10, 2011
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PETBrenda F Kurland, Lanell M Peterson, Jean H Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2016
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast CancerBrenda F Kurland, Lanell M Peterson, Jean H Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 11, 2015
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging StudyLi Liu, Ann C Collier, Jeanne M Link, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matterAlexander M Spence, Mark Muzi, David A Mankoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcomeAlexander M Spence, Mark Muzi, Michael M Graham, et al.
Nuclear Medicine and Biology|October 9, 2007
Challenges in clinical studies with multiple imaging probesKenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Molecular Imaging and Biology|October 17, 2018
Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Pageof 6